VALLON PHARMACEU(VLON) - 2024 Q3 - Quarterly Results

Form 8-K Current Report Registrant Information This section provides basic corporate information for GRI Bio, Inc., including its address, stock exchange listing, and its classification as an emerging growth company - GRI Bio, Inc. is a Delaware-incorporated company with principal executive offices located at 2223 Avenida de la Playa, 208, La Jolla, CA 92037[2] Stock Registration Details | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :--- | :--- | :--- | | Common Stock, par value $0.0001 per share | GRI | The Nasdaq Capital Market | - The company is identified as an 'Emerging Growth Company' under SEC rules[4] Item 2.02 Results of Operations and Financial Condition On November 14, 2024, GRI Bio, Inc. issued a press release, furnished as Exhibit 99.1, announcing its financial results for the quarter ended September 30, 2024, along with a business update. The information is explicitly 'furnished' and not 'filed' for liability purposes under the Securities Exchange Act - The company announced its financial results for the quarter ended September 30, 2024, via a press release on November 14, 2024[5] - The information, including the press release (Exhibit 99.1), is being 'furnished' and not 'filed' with the SEC, which has implications for legal liability under the Securities Exchange Act of 1934[6] Item 9.01 Financial Statements and Exhibits This section lists the exhibits filed with the Form 8-K, which include the press release detailing the financial results and an interactive data file for reporting List of Exhibits | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release issued by GRI Bio, Inc., dated November 14, 2024 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures The report was formally authorized and signed on November 14, 2024, by the company's Chief Financial Officer, Leanne Kelly - The report was signed on behalf of GRI Bio, Inc. on November 14, 2024[10] - The signatory was Leanne Kelly, in her capacity as Chief Financial Officer[11]